News

Euclid Announces ABB Optical Group as Licensed Manufacturer and Distributor of Euclid Ortho-K Lenses

Euclid Vision Corporation (Euclid), a global leader in advanced orthokeratology (Ortho-K) lenses and proactive myopia management initiatives, is pleased to announce ABB Optical Group as a licensed manufacturer and distributor of the company’s Ortho-K lenses. ABB, known as the largest distributor of soft lenses in the United States, supplies nearly two-thirds of eye care professionals (ECPs) across the United States with optical products, services, and business solutions.

Given ABB’s reach, this new collaboration will provide greater access to Euclid’s clinically proven Ortho-K contact lenses to a much wider audience of ECPs. “The manufacturing and distribution arrangement capitalizes on the strengths of two leading companies in the specialty contact lens arena and manifests our shared vision of growing accessibility to myopia management products and services,” said Joseph Boorady, president and CEO, Euclid.

Euclid is the manufacturer of the Euclid Emerald® and Euclid MAX™ Ortho-K contact lenses, which are worn overnight and are designed to reshape the cornea, so patients wake up to clear vision. Euclid’s Ortho-K lenses have a unique design that yields an 87% first fit success¹ without requiring a trial set. ABB is well-equipped to support the manufacturing of Euclid’s lenses with their decades of gas permeable (GP) and custom soft lens manufacturing and specialty vision products distribution expertise.

“We are excited to work with Euclid and expand our licensed manufacturing, distribution, and myopia management product offerings with the addition of Euclid MAX lenses, a next generation Ortho-K product. Recognizing the continued rise of myopia as a serious eye-health issue, we are proud to bring an innovative Ortho-K design, which has the highest Dk of any US overnight Ortho-K brand, to our ABB customers.” said Aaron See, senior vice president of manufacturer partnerships, ABB.

Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050.² “Increased accessibility to Euclid’s Ortho-K lenses means ABB’s customers can broaden their myopia management initiatives and help more myopic children at a critical time in the myopia epidemic,” said Nitin Jain, chief commercialization officer, Euclid. “This trend presents both a clinical challenge and practice management opportunity for ECPs poised to best serve their myopic patients. Together with ABB, we can provide easier access to myopia management products to help mitigate the extent of this epidemic,” added Jain.

Visit the Euclid MAX landing page to get started.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,